FCF YoY
+45.39%
OCF YoY
+45.41%
Capex Change
+10.0K
FCF Conversion Δ
—
Free cash flow bridge for Spruce Biosciences (SPRB) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: $24.4M
FCF bridge breakdown for Spruce Biosciences (SPRB) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | -$53.7M | — |
| Operating Cash Flow | $24.4M | +100.0% |
| Capital Expenditure | -$10K | -0.0% |
| Free Cash Outflow | -$29.3M | — |
- Prior Free Cash Flow-$53.7M
- Operating Cash Flow$24.4M
- Capital Expenditure-$10K
- Free Cash Outflow-$29.3M
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Spruce Biosciences (SPRB) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.